Systemic therapy in metastatic renal cell carcinoma

[1]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[2]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[3]  M. Staehler,et al.  SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. , 2015, European urology.

[4]  B. Rini,et al.  17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC , 2015 .

[5]  R. Motzer,et al.  3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) , 2015 .

[6]  R. Motzer,et al.  Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). , 2015 .

[7]  A. Stenzl,et al.  Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma , 2015, Human vaccines & immunotherapeutics.

[8]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.

[9]  P. Karakiewicz,et al.  Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence , 2014, International journal of nephrology and renovascular disease.

[10]  Tae Min Kim,et al.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Porta,et al.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[12]  M. Staehler,et al.  SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). , 2014 .

[13]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[14]  T. Choueiri,et al.  Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.

[15]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[16]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[17]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[18]  S. Shariat,et al.  The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology. , 2013, European urology.

[19]  Lauren McCann,et al.  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.

[20]  S. Stevanović,et al.  Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy , 2013, World Journal of Urology.

[21]  J. Dutcher,et al.  Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis , 2013, British Journal of Cancer.

[22]  C. Porta,et al.  Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. , 2012, European journal of cancer.

[23]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[24]  M. Rosenblum,et al.  Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel–Lindau gene and hypoxia-inducible factor pathway-related proteins , 2011, Modern Pathology.

[25]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[26]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[27]  A. Ravaud,et al.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Mclaughlin,et al.  Epidemiologic characteristics and risk factors for renal cell cancer , 2009, Clinical epidemiology.

[31]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[32]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[33]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[34]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[35]  R. Motzer,et al.  Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[36]  N. Rioux-Leclercq,et al.  Understanding the importance of smart drugs in renal cell carcinoma. , 2006, European urology.

[37]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[38]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[39]  K. Bensalah,et al.  Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. , 2016, European urology.

[40]  J. Himmelfarb,et al.  Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .

[41]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.